Taysha Gene Therapies (NASDAQ:TSHA – Free Report) had its price objective boosted by Cantor Fitzgerald from $6.00 to $7.00 in a research note released on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.
TSHA has been the subject of several other research reports. Needham & Company LLC restated a buy rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, September 20th. Chardan Capital restated a buy rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, August 15th. Truist Financial decreased their target price on shares of Taysha Gene Therapies from $6.00 to $5.00 and set a buy rating for the company in a research report on Wednesday, September 20th. Robert W. Baird boosted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company an outperform rating in a research report on Tuesday, August 15th. Finally, Canaccord Genuity Group cut their price target on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a buy rating for the company in a report on Wednesday, September 20th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $5.89.
Taysha Gene Therapies Stock Performance
Insider Buying and Selling at Taysha Gene Therapies
In other Taysha Gene Therapies news, CFO Kamran Alam sold 33,000 shares of the stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $2.33, for a total value of $76,890.00. Following the transaction, the chief financial officer now directly owns 258,042 shares in the company, valued at $601,237.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.25% of the stock is owned by insiders.
Institutional Investors Weigh In On Taysha Gene Therapies
Several large investors have recently modified their holdings of the company. Capital Investment Advisors LLC acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth $32,000. AQR Capital Management LLC acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth $38,000. Maven Securities LTD purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $34,000. Lee Financial Co acquired a new position in shares of Taysha Gene Therapies during the third quarter worth about $63,000. Finally, Kovitz Investment Group Partners LLC raised its holdings in Taysha Gene Therapies by 66.7% during the third quarter. Kovitz Investment Group Partners LLC now owns 25,000 shares of the company’s stock worth $79,000 after purchasing an additional 10,000 shares in the last quarter. 25.91% of the stock is owned by institutional investors and hedge funds.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
- Five stocks we like better than Taysha Gene Therapies
- How to Invest in Semiconductors
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- What are stock market earnings reports?
- MarketBeat Week in Review – 11/13 – 11/17
- Trading Halts Explained
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.